Table II.
Treatment exposure
| Parameter | DLBCL (n = 27) | FL (n = 10) | MCL (n = 18) | MZL (n = 9) | CLL/SLL (n = 17) | HL (n = 18) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment duration [months]: | ||||||||||||
| Median | 4.5 | 5.3 | 5.6 | 4.9 | 5.3 | 5.3 | ||||||
| Range | (0.7–37.3) | (1.7–7.6) | (1.7–28.7) | (1.6–6.4) | (3.6–9) | (0.3–22) | ||||||
| No. of cycles: | ||||||||||||
| Median | 4 | 6 | 6 | 6 | 6 | 6 | ||||||
| Range | (1–8) | (2–9) | (2–38) | (2–8) | (4–6) | (1–10) | ||||||
| Bendamustine dosage, n (%): | ||||||||||||
| 90 mg/m2 | 17 | (63) | 8 | (80) | 16 | (88.9) | 9 | (100) | 17 | (100) | 14 | (77.8) |
| 100 mg/m2 | 9 | (33.3) | 2 | (20) | 2 | (11.1) | 0 | (0) | 0 | (0) | 1 | (5.6) |
| 120 mg/m2 | 1 | (3.7) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 3 | (16.7) |
Note: The percentages in parentheses are column percentages. CLL/SLL – chronic lymphocytic lymphoma/small lymphocytic lymphoma, DLBCL – diffuse large B-cell lymphoma, FL – follicular lymphoma, HL – Hodgkin lymphoma, MCL – mantle cell lymphoma, MZL – marginal zone lymphoma.